Clear Route update

Putting on a conference is something like going on vacation - when you get back, the desk is groaning with undone work and when you recover it's three weeks later. So it hasn't been entirely surprising that we've been mum about the one-day investment conference that BioCentury co-sponsored with The Carson Group at the end of January.

The short summary is that portfolio managers representing about $3.3 billion in biotech share holdings braved the stone cold New York weather to hear 20 companies describe their Clear Route to ROI. Based on the response from both investors and companies, we're hankering to do it again...